Landscapes / Targets
BTK
24 drugs act on BTK, in 141 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs24
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Kinase inhibitor |
Sanofi · Public SNY |
Approved | 25 Nov 2026soonPhase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 25 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia (wAIHA) and 8 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | Nov 2026soonPhase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, CLL and 18 more | ||||
| Open drug page | |||||
Acalabrutinibnot checked |
Kinase inhibitor |
AstraZeneca · Public AZN |
Approved | 15 Feb 2027Phase 3 trial completes | |
| How it works | Blocks a kinase | ||||
| Next date | 15 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL) and 20 more | ||||
| Open drug page | |||||
BTK inhibitor |
Novartis · Public NVS |
Approved | 22 Feb 2027Phase 3 trial completes | ||
| Next date | 22 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Chronic Spontaneous Urticaria, Hidradenitis Suppurativa and 13 more | ||||
| Open drug page | |||||
BTK inhibitor |
Approved | 10 May 2027Phase 4 trial completes | |||
| How it works | Blocks BTK | ||||
| Next date | 10 May 2027 · Phase 4 trial completes | ||||
| Also tested for | Lymphoma, B-Cell, Lymphoma, Non-Hodgkin and 3 more | ||||
| Open drug page | |||||
Bruton's tyrosine kinase inhibitor |
Ono Pharmaceutical +1 · Public GILD |
Approved in Japan | 30 Sep 2027Phase 3 trial completes | ||
| How it works | Blocks BTK | ||||
| Next date | 30 Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma and 4 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Eli Lilly · Public LLY |
Approved | Oct 2027Phase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and 9 more | ||||
| Open drug page | |||||
Bruton's tyrosine kinase inhibitor |
Approved in China | 31 Dec 2027Phase 2 trial completes | |||
| How it works | Blocks BTK | ||||
| Next date | 31 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Mantle Cell Lymphoma, CLL/SLL and 20 more | ||||
| Open drug page | |||||
Bruton's tyrosine kinase inhibitor |
Approved in China | 31 Aug 2028Phase 3 trial completes | |||
| How it works | Blocks BTK | ||||
| Next date | 31 Aug 2028 · Phase 3 trial completes | ||||
| Also tested for | Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies and 7 more | ||||
| Open drug page | |||||
BTK inhibitor (brain-penetrant) |
Sanofi · Public SNY |
Approved in the EU | 30 Apr 2029Phase 3 trial completes | ||
| Next date | 30 Apr 2029 · Phase 3 trial completes | ||||
| Also tested for | Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis and 1 more | ||||
| Open drug page | |||||
BTK inhibitor (non-covalent) |
Roche · Public ROG.SW |
Filed | 8 Jun 2027Phase 2 trial completes | ||
| Next date | 8 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Relapsing Multiple Sclerosis, Multiple Sclerosis, Primary Progressive and 1 more | ||||
| Open drug page | |||||
Ibrutinibnot checked |
BTK inhibitor |
Johnson & Johnson (Janssen) · Public JNJ |
Phase 3 | 31 Dec 2026Phase 3 trial completes | |
| How it works | Blocks BTK | ||||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma and 12 more | ||||
| Open drug page | |||||
— |
Phase 3 | Mar 2027Phase 1/2 trial completes | |||
| Next date | Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, B-cell Malignancy and 18 more | ||||
| Open drug page | |||||
Bruton's tyrosine kinase inhibitor |
Merck & Co. · Public MRK |
Phase 3 | 19 May 2027Phase 3 trial completes | ||
| How it works | Blocks BTK | ||||
| Next date | 19 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and 20 more | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Apr 2028Phase 3 trial completes | |||
| Next date | 30 Apr 2028 · Phase 3 trial completes | ||||
| Also tested for | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2026Phase 2 trial completes | |||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | B-cell Lymphoma, Systemic Lupus Erythematosus | ||||
| Open drug page | |||||
— |
Phase 2 | 31 Dec 2028Phase 2 trial completes | |||
| Next date | 31 Dec 2028 · Phase 2 trial completes | ||||
| Also tested for | Minimal Change Disease (MCD), IgA Nephropathy (IgAN) and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | 10 Oct 2029Phase 2 trial completes | |||
| Next date | 10 Oct 2029 · Phase 2 trial completes | ||||
| Also tested for | B-Cell Malignancies, Mantle Cell Lymphoma (MCL) | ||||
| Open drug page | |||||
Ibrutinibnot checked |
BTK inhibitor |
Phase 1/2 | — | ||
| How it works | Blocks BTK | ||||
| Also tested for | Breast Neoplasms, Malignant Neoplasm of Breast | ||||
| Open drug page | |||||
— |
Phase 1 | Aug 2027Phase 1 trial completes | |||
| Next date | Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Malignancies | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 20 of 24 drugs. The other 4 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026